Latest News and Press Releases

UPPSALA, SWEDEN – LIDDS AB (publ) tillkännagav i dag att forskningssamarbetet med Johnson & Johnson Enterprise Innovation Inc har fortsatt in i nästa fas. ”Genom ett starkt samarbete har...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the R&D project with Johnson & Johnson Enterprise Innovation Inc. has progressed into next phase. “On the back of a strong...

UPPSALA, SVERIGE – LIDDS AB (publ) tillkännagav i dag att den systemiska exponeringen av docetaxel efter behandling av solida tumörer med NanoZolid®-formulerad docetaxel är låg och att studien visar...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both...

UPPSALA, SWEDEN – LIDDS AB (publ) tillkännagav i dag att Matthew Lindon har utsetts till Chief Scientific Officer (CSO) för LIDDS AB. Matthew Lindon har över 20 års erfarenhet av drug discovery och...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Matthew Lindon has been appointed Chief Scientific Officer (CSO) of LIDDS AB. Matthew Lindon has over 20 years experience of drug discovery and...

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in China. The...

JANUARY – SEPTEMBER 2021 Net sales amounted to MSEK 1.2 (0.0)Operating expenses amounted to MSEK -29,5 (-19,8)Profit/loss before and after tax amounted to MSEK -28.4 (-19.8)Earnings per share...

November 17, 2021 Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS UPPSALA, SWEDEN – LIDDS AB (publ) today announced the composition of the Nomination Committee for...

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Johan Harmenberg has been appointed Chief Medical Officer (CMO) of LIDDS AB. Johan Harmenberg has extensive experience from the pharmaceutical...